Using remote ischemic conditioning to treat high blood pressure

Efficacy and Safety of Remote Ischemic Conditioning in the Treatment of Essential Hypertension

This study is testing if a new technique called remote ischemic conditioning can help lower blood pressure in adults with high blood pressure.

Quick facts

• Phase: Not applicable
• Study type: Interventional
• Enrollment: 102 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: The First Hospital of Jilin University (Academic / other)
• Locations: 1 site (Changchun, Jilin)
• Trial ID: NCT05910242 on ClinicalTrials.gov

What this trial studies

This study investigates the efficacy and safety of remote ischemic conditioning as a treatment for essential hypertension. It aims to explore how this technique can improve vascular function, reduce sympathetic nervous system activity, and modulate immune and inflammatory responses, potentially leading to lower blood pressure. Participants will undergo either remote ischemic conditioning or a sham procedure to assess the treatment's effectiveness. The study will include adults with high blood pressure who meet specific criteria.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 and older with systolic blood pressure of 140 mmHg or higher.

Not a fit: Patients with secondary hypertension or severe organ dysfunction may not benefit from this study.

Why it matters

Potential benefit: If successful, this approach could provide a non-invasive treatment option for managing essential hypertension.

How similar studies have performed: Other studies have shown promising results with remote ischemic conditioning, suggesting potential for success in this approach.

Eligibility criteria

Inclusion Criteria:

1. Age≥18 years, regardless of sex;
2. Patients with systolic blood pressure ≥140mmHg with or without taking oral antihypertensive drugs
3. Signed and dated informed consent is obtained

Exclusion Criteria:

1. Secondary hypertension;
2. Clinical blood pressure ≥ 180/110 mmHg or 24-hour mean arterial pressure ≥ 170/100 mmHg;
3. Severe organ dysfunction or failure;
4. Severe hematologic disorders or significant coagulation abnormalities;
5. History of atrial fibrillation or myocardial infarction within 6 months;
6. Individuals who had contraindication of remote ischemic conditioning, such as severe soft tissue injury, fracture or vascular injury in the upper limb, acute or subacute venous thrombosis, arterial occlusive disease, subclavian steal syndrome, etc;
7. Individuals who will or have received anticoagulant therapy with drugs such as dabigatran, rivaroxaban, warfarin, etc; ;
8. Pregnant or lactating women;
9. Those who are participating in other clinical research or has participated in other clinical research or has participated in this study within 3 months prior to enrollment;
10. Other conditions that the researchers think are not suitable for the project.

Where this trial is running

Changchun, Jilin

• The First Hospital of Jilin University — Changchun, Jilin, China (Recruiting)

Study contacts

• Study coordinator: Yi Yang, MD,PhD

Conditions Essential Hypertension